Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility

References

• Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, Kornetova E, et al. 2009. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry 33: 475–481.
   PubMed Web of Science ®Google Scholar
• Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Wilffert B, Semke A, Fedorenko O, et al. (2010). Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol 25: 84–91.
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. 2010, Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 67: 255–262.
   PubMed Web of Science ®Google Scholar
• Basile VS, Özdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, et al. 2000. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 5: 410–417.
   PubMed Web of Science ®Google Scholar
• Brosen K. 1996. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 18: 393–396.
   PubMed Web of Science ®Google Scholar
• Correll CU, Schenk EM. 2008. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatr 21: 151–156.
   PubMed Web of Science ®Google Scholar
• Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. 2010. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C> A polymorphism. Eur J Clin Pharmacol 66: 697–703.
   PubMed Web of Science ®Google Scholar
• D’Souza MS, Markou A. 2012. Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmaco logy 62: 1564–1573.
   PubMed Web of Science ®Google Scholar
• Flockhart DA. 2007. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). Accessed 3 July 2014.
   Google Scholar
• Fu Y, Fan CH, Deng HH, Hu SH, Lv DP, Li LH, et al. 2006. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 27: 328–332.
   PubMed Web of Science ®Google Scholar
• Gervasini G, Carrillo JA, Benitez J.2004. Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin Pharmacokinet 43: 693–706.
   PubMed Web of Science ®Google Scholar
• Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, et al. 2009. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 10: 769–778.
   PubMed Web of Science ®Google Scholar
• Gureje O. 1988. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. J Neurol Neurosurg Psychiatry 51: 1525–1530.
   PubMed Web of Science ®Google Scholar
• Hazari N, Kate N, Grover S. 2013. Clozapine and tardive movement disorders: a review. Asian J Psychiatr 6: 439–451.
   PubMedGoogle Scholar
• Ivanova SA, Loonen AJ, Pechlivanoglou P, Freidin MB, Al Hadithy AF, Rudikov EV, et al. 2012a. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl Psychiatry 2:e67.
   PubMed Web of Science ®Google Scholar
• Ivanova SA, Al Hadithy AF, Brazovskaya N, Semke A, Wilffert B, Fedorenko O, et al. 2012b. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol 27: 334–337.
   PubMed Web of Science ®Google Scholar
• Ivanova SA, Geers LM, Al Hadithy AF, Pechlivanoglou P, Semke AV, Vyalova NM, et al. 2014. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 50: 172–177.
   PubMed Web of Science ®Google Scholar
• Koola MM, Tsapakis EM, Wright P, Smith S, Kerwin Rip RW, Nugent KL, Aitchison KJ. 2014. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?J Psychopharmacol 28: 665–670.
   PubMed Web of Science ®Google Scholar
• Latimer PR. 1995. Tardive dyskinesia: a review. Can J Psychiatry 40(Suppl 2):S49–54.
   Google Scholar
• Loonen AJ, Doorschot CH, van Hemert DA, Oostelbos MC, Sijben AE. 2000. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity. Int J Neuropsychopharmacol 3: 285–296.
   PubMed Web of Science ®Google Scholar
• Loonen AJ, Doorschot CH, van Hemert DA, Oostelbos MC, Sijben AE. 2001. The schedule for the assessment of drug- induced movement disorders (SADIMoD): inter-rater reliability and construct validity. Int J Neuropsychopharmacol 4: 347–360.
   PubMed Web of Science ®Google Scholar
• Loonen AJ, van Praag HM. 2007. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. J Clin Psychopharmacol 27: 423–430.
   PubMed Web of Science ®Google Scholar
• Loonen AJ, Ivanova SA. 2013. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr 18: 15–20.
   PubMed Web of Science ®Google Scholar
• Meyer UA. 1994. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA 91: 1983–1984.
   PubMed Web of Science ®Google Scholar
• Miller RT, Miksys S, Hoffmann E, Tyndale RF.2014. Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys. J Pharmacol 171: 3077–3088.
   Google Scholar
• Mookhoek EJ, Loonen AJ. 2004. Retrospective evaluation of the effect of omeprazole on clozapine metabolism. Pharm World Sci 26: 180–182.
   PubMedGoogle Scholar
• Özdemir V, Basile VS, Masellis M, Kennedy JL. 2001. Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes. J Biochem Biophys Methods 47: 151–157.
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414–423.
   PubMed Web of Science ®Google Scholar
• Stamou M, Wu X, Kania-Korwel I, Lehmler HJ, Lein PJ. 2014. Cytochrome p450 mRNA expression in the rodent brain: species-, sex-, and region-dependent differences. Drug Metab Dispos 42: 239–244.
   PubMed Web of Science ®Google Scholar
• Taylor D. 1997. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 171: 109–112.
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL, Thelma BK. 2007. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C> T polymorphism. Pharmacogenomics J 7: 305–311.
   PubMed Web of Science ®Google Scholar
• Wang L, Hu Z, Deng X, Wang Y, Zhang Z, Cheng ZN. 2013. Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers. Basic Clin Pharmacol Toxicol 112: 257–263.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E. 2009. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 11: 481–494.
   PubMed Web of Science ®Google Scholar